Patients taking Eli Lilly and Co.’s blockbuster weight-loss shot were 94% less likely to develop diabetes in a three-year study that illuminates the long-term health benefits of treating obesity. It’s ...
RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of ...
Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone. Study Design: Using US health ...
Comprehensive analysis confirms safety and strong accuracy of Glucotrack's innovative blood-based continuous glucose monitoring technology, with MARD of 7.7% RUTHERFORD, N.J. and STOCKHOLM, June 25, ...
ABINGDON, England--(BUSINESS WIRE)--GlySure Limited today announced publication of a manuscript in the Journal of Diabetes Science and Technology, which validates the safety and performance of the ...
A study shows that in healthcare electronics, it is primarily the electronics in the devices that burden the environment.
Glucotrack (NASDAQ:GCTK) on Tuesday reported the successful completion of its first in human clinical study, sending shares up ~60% in the morning trade. This study represents first real-time, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback